May 2006

Peginterferon Alfa-2b for Mycosis Fungoides

Author Affiliations

Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006

Arch Dermatol. 2006;142(5):647-651. doi:10.1001/archderm.142.5.649

Currently, peginterferon alfa-2b plus ribavirin has been shown to be the best available therapy for patients with chronic hepatitis C virus (HCV) infection.1 Peginterferon alfa-2b (a 12-kDa linear polyethylene glycol moiety) plus ribavirin produces a significantly improved and sustained antiviral response compared with interferon alfa-2b plus ribavirin.1 Peginterferon alfa-2b has an extended serum half-life that provides constant viral suppression for 7 days, thus allowing once-weekly dosing and an enhanced clinical efficacy.1 While interferon alfa-2b has been used to treat T-cell lymphoma,2,3 we report herein the significant efficacy of peginterferon alfa-2b for treatment of skin lesions caused by mycosis fungoides (MF).